MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
127.17
-7.67
-5.69%
After Hours: 127.17 0 0.00% 19:30 11/12 EST
OPEN
134.19
PREV CLOSE
134.84
HIGH
134.67
LOW
126.94
VOLUME
685.03K
TURNOVER
--
52 WEEK HIGH
142.92
52 WEEK LOW
58.87
MARKET CAP
10.86B
P/E (TTM)
-35.1454
1D
5D
1M
3M
1Y
5Y
1D
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha · 3d ago
Weekly Report: what happened at KYMR last week (1102-1106)?
Weekly Report · 3d ago
Canaccord Genuity Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
TipRanks · 11/03 12:55
Kymera Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 11/02 20:56
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
Benzinga · 11/02 20:46
Leerink Partners Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
TipRanks · 11/02 16:42
S&P 500 Futures Climb In Premarket Trading; Moog, Kymera Therapeutics Lead
Dow Jones · 11/02 12:30
Kymera Therapeutics price target raised to $170 from $139 at Barclays
TipRanks · 11/02 10:35
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.